mRNA therapies powered by
Evolutionary
Intelligence
Advancing longevity therapies
with cross-species validated natural variants
Explore our platform
with cross-species validated natural variants
Tackling the longevity challenge through evolution
Nature’s ultimate optimization engine
caVos identifies genetic variants conserved across long-lived species
to develop first-in-class mRNA therapies validated by nature for efficacy and safety
to develop first-in-class mRNA therapies validated by nature for efficacy and safety
Bowhead whale
Life span>200 years
Naked mole rat
Life span ~40 years
Turritopsis Dohrnii
Immortal jellyfish
Greenland shark
Life span ~400 years
Longevity-related super-traits in nature
Unique super-traits
conserved across species
conserved across species
Therapeutic effects
already proven in nature
already proven in nature
Cross-species convergence
validates efficacy and safety potential
validates efficacy and safety potential
caVos established a proprietary atlas of variants
Validated across species
A systematic, evolution-guided approach to discover high-potential variants
Evolutionary
data
data
Artificial
intelligence
intelligence
Evolutionary
intelligence
intelligence
Cross-species genomic
comparison
Selecting extreme long-lived
and short-lived species from
diverse evolutionary branches
Variant
identification
Pinpointing minimal genetic
changes conserved in long-lived
species
Correlation
and prioritization
Prioritizing variants most strongly
correlated with longevity across
extensive cross-species datasets
Atlas of variants
validated by nature
Building a nature-validated atlas of
variants with validated efficacy
potential and reduced toxicity risk
Evolutionary
data
data
Cross-species genomic
comparison
Selecting extreme long-lived
and short-lived species from
diverse evolutionary branches
Artificial
intelligence
intelligence
Variant
identification
Pinpointing minimal genetic
changes conserved in long-lived
species
Correlation
and prioritization
Prioritizing variants most strongly
correlated with longevity across
extensive cross-species datasets
Evolutionary
intelligence
intelligence
Atlas of variants
validated by nature
Building a nature-validated atlas of
variants with validated efficacy
potential and reduced toxicity risk
The first evolution-derived atlas of
Therapeutic genetic variants
260 longevity-associated
variants
variants
anti-cancer variants
fibrosis variants
Initially focused on
fibrosis and oncology
97
anti-cancer variants
Including 34 with strong
cancer-fighting potential
Including 34 with strong
cancer-fighting potential
37
fibrosis variants
Found in top long-lived species
Found in top long-lived species
POC in prioritized
selected variants
3
validated in-vitro
across multiple cancer cell lines
across multiple cancer cell lines
4
validated in-vitro
for fibrosis
for fibrosis
Next steps
In-vivo
validation
validation
Guided by strong in-vitro efficacy
and validated delivery platform
and validated delivery platform
Multi-target
mRNA therapy
mRNA therapy
Combining complementary
effects of multiple variants
effects of multiple variants
Our team
Haim Belinson, PhD
CEO
Ifat Keydar, PhD
Bioinformatics Scientist
Ora Haimov, PhD
Senior Scientist
Daniel Blumenkrants, Msc
Scientist
Advisors
Yuval Tabach, PhD
Founder, Professor of Genomics, Evolution, and Data Science.
The Hebrew University Medical School
The Hebrew University Medical School
Prof. Dan Peer
RNA therapeutics
innovation
innovation
Tamar Grossman, PhD
Gene therapy and
drug delivery
drug delivery
Michelle Lynn Hall, PhD
RNA therapeutics and
AI-driven drug discovery
AI-driven drug discovery
Jim Weissman
Business
Development
Development
Investors
Contact us
Let’s advance evolution-guided mRNA
therapeutics together
Collaborate with us to research and
expand our atlas of 260 cross-species
validated variants, accelerate lead
programs, and co-develop
next-generation mRNA therapies for
longevity-related diseases.
expand our atlas of 260 cross-species
validated variants, accelerate lead
programs, and co-develop
next-generation mRNA therapies for
longevity-related diseases.